BR9713921A - Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa - Google Patents

Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa

Info

Publication number
BR9713921A
BR9713921A BR9713921A BR9713921A BR9713921A BR 9713921 A BR9713921 A BR 9713921A BR 9713921 A BR9713921 A BR 9713921A BR 9713921 A BR9713921 A BR 9713921A BR 9713921 A BR9713921 A BR 9713921A
Authority
BR
Brazil
Prior art keywords
factor
logician
inhibition
modulated
compound
Prior art date
Application number
BR9713921A
Other languages
English (en)
Portuguese (pt)
Inventor
Yong Mi Choi-Sledeski
Henry W Pauls
Jeffrey N Barton
William R Ewing
Daniel M Green
Michael R Becker
Original Assignee
Rhone Poulenc Rorer Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Pharma filed Critical Rhone Poulenc Rorer Pharma
Publication of BR9713921A publication Critical patent/BR9713921A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9713921A 1996-12-13 1997-12-03 Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa BR9713921A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3315996P 1996-12-13 1996-12-13
PCT/US1997/022406 WO1998025611A1 (en) 1996-12-13 1997-12-03 Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds

Publications (1)

Publication Number Publication Date
BR9713921A true BR9713921A (pt) 2000-03-21

Family

ID=21868858

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713921A BR9713921A (pt) 1996-12-13 1997-12-03 Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa

Country Status (23)

Country Link
EP (1) EP0944386B1 (enExample)
JP (1) JP4223560B2 (enExample)
KR (1) KR20000057528A (enExample)
CN (1) CN1244798A (enExample)
AP (1) AP1032A (enExample)
AT (1) ATE224192T1 (enExample)
AU (1) AU726637B2 (enExample)
BG (1) BG103558A (enExample)
BR (1) BR9713921A (enExample)
CA (1) CA2274686C (enExample)
DE (1) DE69715658T2 (enExample)
DK (1) DK0944386T3 (enExample)
EA (1) EA002817B1 (enExample)
ES (1) ES2184145T3 (enExample)
HU (1) HUP9904188A3 (enExample)
IL (1) IL130152A0 (enExample)
NO (1) NO312416B1 (enExample)
OA (1) OA11062A (enExample)
PL (1) PL333921A1 (enExample)
PT (1) PT944386E (enExample)
SK (1) SK71299A3 (enExample)
WO (1) WO1998025611A1 (enExample)
ZA (1) ZA9711207B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281227B1 (en) * 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
US6602864B1 (en) * 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
AR016817A1 (es) * 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
WO1999011658A1 (en) 1997-08-29 1999-03-11 Proteus Molecular Design Ltd. Meta-benzamidine derivatives as serin protease inhibitors
KR20010015639A (ko) 1997-09-30 2001-02-26 스즈키 다다시 술포닐 유도체
CN1302292A (zh) 1998-03-19 2001-07-04 味之素株式会社 氨基异喹啉衍生物
US6747023B1 (en) * 1998-08-11 2004-06-08 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0127568D0 (en) 2001-11-16 2002-01-09 Glaxo Group Ltd Chemical compounds
WO2003106445A1 (en) * 2002-06-12 2003-12-24 Qsi Pharma A/S Compounds and methods for controlling bacterial virulence
CA2507707C (en) 2002-12-03 2011-06-21 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
JP2008509222A (ja) * 2004-08-09 2008-03-27 グラクソ グループ リミテッド 抗菌剤
FR2890072A1 (fr) 2005-09-01 2007-03-02 Fournier S A Sa Lab Nouveaux composesde pyrrolopyridine
EP1932839A4 (en) * 2005-09-06 2014-09-10 Shionogi & Co INDOLECARBOXYLATE ACID DERIVATIVE HAVING ANTAGONIST EFFECT OF THE PGD2 RECEPTOR
FR2955110A1 (fr) 2010-01-08 2011-07-15 Fournier Lab Sa Nouveaux derives de type pyrrolopyridine benzoique
EP2606893A1 (en) * 2011-12-21 2013-06-26 Sanofi Sulphonylaminopyrrolidinone derivatives, their preparation and their therapeutic application
CN104098497B (zh) * 2014-06-17 2016-04-13 王庚禹 一种新的酰胺类化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121947A1 (de) * 1991-07-03 1993-01-07 Basf Ag 2-(3-(4-amidino-phenyl))-propionsaeurederivate, ihre herstellung und verwendung
WO1995035311A1 (en) * 1994-06-17 1995-12-28 Corvas International, Inc. 3-amino-2-oxo-1-piperidineacetic derivatives as enzyme inhibitors
US5612353A (en) * 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds

Also Published As

Publication number Publication date
DE69715658D1 (de) 2002-10-24
EP0944386B1 (en) 2002-09-18
SK71299A3 (en) 2000-12-11
NO992853L (no) 1999-08-10
EA199900542A1 (ru) 2000-02-28
WO1998025611A1 (en) 1998-06-18
EP0944386A1 (en) 1999-09-29
EA002817B1 (ru) 2002-10-31
BG103558A (en) 2000-04-28
ZA9711207B (en) 1998-07-20
EP0944386A4 (en) 2001-04-11
ATE224192T1 (de) 2002-10-15
AP9901552A0 (en) 1999-06-30
CA2274686C (en) 2009-02-03
CA2274686A1 (en) 1998-06-18
PL333921A1 (en) 2000-01-31
CN1244798A (zh) 2000-02-16
NO312416B1 (no) 2002-05-06
KR20000057528A (ko) 2000-09-25
HUP9904188A3 (en) 2003-02-28
DK0944386T3 (da) 2003-01-27
DE69715658T2 (de) 2003-05-22
NO992853D0 (no) 1999-06-11
AU726637B2 (en) 2000-11-16
AP1032A (en) 2001-12-24
AU5518298A (en) 1998-07-03
OA11062A (en) 2002-03-11
PT944386E (pt) 2003-01-31
ES2184145T3 (es) 2003-04-01
JP4223560B2 (ja) 2009-02-12
JP2001506630A (ja) 2001-05-22
IL130152A0 (en) 2000-06-01
HUP9904188A1 (hu) 2000-06-28

Similar Documents

Publication Publication Date Title
BR9713921A (pt) Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa
BR9806060A (pt) Composto, composição farmacêutica e processos para tratar um paciente sofrendo de um estado doentio, para inibir o fator xa, e, para inibir a formação de trombina.
CA2238465A1 (fr) Composes triaromatiques, compositions les contenant et utilisations
CA2191789A1 (fr) Composes biaromatiques portant un groupement adamantyl en ortho, compositions pharmaceutiques et cosmetiques les contenant et utilisations de ces compositions
MX9709977A (es) Compuestos de (acido sulfinico, acido sulfonico, sulfonilamino o sulfinilamino) n-[(aminoiminometil) fenilalquil] azaheterociclilamida sustituidos.
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
BR9612423A (pt) Composto, composição farmacêutica, e, processo para tratar um estado doentio.
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
BE904421A (fr) Derives heterocycliques aromatiques et leur application dans les domaines therapeutique et cosmetique.
CA2218766A1 (fr) Composes bicycliques-aromatiques
FI972628A0 (fi) Uudet sulfonamidit
BRPI9710372B8 (pt) composto, e, composição farmacêutica.
BR0214967A (pt) Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente
WO2001039759A3 (en) Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
CA2191790A1 (fr) Composes biaromatiques portant un groupement adamantyl en para, compositions pharmaceutiques et cosmetiques les contenant et utilisations de ces compositions
NO166939C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
BR9910899A (pt) Compostos de ácido sulfÈnico ou sulfonilamino n-(hetero-aralquil)-azaeterocicliamida
BR9902808A (pt) Compostos, composição farmacêutica, composição cosmética e uso de uma composição cosmética
CA2147807A1 (fr) Composes bicycliques-aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CA2147808A1 (fr) Composes bi-aromatiques acetylenes a groupement adamantyle, compositions pharmaceutiques et cosmetiques les contenant et utilisations
CA2215470A1 (fr) Composes biaryles heterocycliques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
KR970025615A (ko) 암 전이 억제제
EA199700381A1 (ru) Диароматические соединения пропинила или диенила, промежуточные соединения, фармацевтические и косметические композиции на основе указанных соединений и применение косметических композиций
DK0658553T3 (da) Hidtil ukendte polycykliske aromatiske forbindelser, farmaceutiske præparater og kosmetiske sammensætninger indeholdende di

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1833 DE 21/02/2006.